Details of the Drug

General Information of Drug (ID: DMHIDCJ)

Drug Name

Octreotide

Synonyms

Longastatin; Octreotida; Octreotidum; Sandostatine; Octreotida [Spanish]; Octreotide Acetate Salt; Octreotidum [Latin]; DRG-0115; HS-2020; Octreotide-LAR; SAN 201-995; SM 201-995; SMS 201-995; Sandostatin (TN); Sandoz 201-995; Octreotide (USAN/INN); Octreotide [USAN:INN:BAN]; SMS-201-995; Zacycloicosane-4-carboxamide acetate; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide; 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Acromegaly	5A60.0	Approved	[1], [2]

Therapeutic Class

Anabolic Agents

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 4

Molecular Weight (mw)

1019.2

Topological Polar Surface Area (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.67C2.5 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance: The total body clearance of drug is 7-10 L/h [3]
Elimination: About 32% of an oral octreotide dose is excreted into the urine and 30-40% is excreted by the liver into the feces [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 0.2 hours [3]
Metabolism: The drug is metabolized via the liver [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.021 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.35% [7]
Vd: The volume of distribution (Vd) of drug is 13.6 L [3]

Chemical Identifiers

Formula: C49H66N10O10S2
IUPAC Name: (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
Canonical SMILES: C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O
InChI: InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1
InChIKey: DEQANNDTNATYII-OULOTJBUSA-N

Cross-matching ID

PubChem CID: 448601
CAS Number: 83150-76-9
DrugBank ID: DB00104
TTD ID: D02XIY
VARIDT ID: DR01163

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Somatostatin receptor type 2 (SSTR2)	TTZ6T9E	SSR2_HUMAN	Binder	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Acromegaly

ICD Disease Classification

5A60.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Somatostatin receptor type 2 (SSTR2)	DTT	SSTR2	9.79E-07	-0.38	-0.65
Multidrug resistance-associated protein 2 (ABCC2)	DTP	MRP2	7.16E-01	-1.28E-02	-6.06E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Octreotide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylergonovine	DMBEX4O	Moderate	Decreased metabolism of Octreotide caused by Methylergonovine mediated inhibition of CYP450 enzyme.	Abortion [JA00]	[30]
Gilteritinib	DMWQ4MZ	Moderate	Decreased metabolism of Octreotide caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[31]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Octreotide caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[32]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Octreotide caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Dofetilide	DMPN1TW	Moderate	Decreased metabolism of Octreotide caused by Dofetilide mediated inhibition of CYP450 enzyme.	Cardiac arrhythmia [BC9Z]	[33]
PF-04449913	DMSB068	Moderate	Decreased metabolism of Octreotide caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[34]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Octreotide caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[35]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Octreotide caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[36]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Octreotide caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[31]
177Lu-DOTATATE	DMT8GVU	Moderate	Interference of cell/tissue uptake of Octreotide by 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[37]
MK-1439	DM215WE	Minor	Decreased metabolism of Octreotide caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Octreotide caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Octreotide caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[40]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of Octreotide caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[41]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Octreotide caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[42]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Octreotide caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[31]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Octreotide caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[43]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of Octreotide caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[44]
Ibrutinib	DMHZCPO	Moderate	Decreased metabolism of Octreotide caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[45]
Methysergide	DM1EF73	Moderate	Decreased metabolism of Octreotide caused by Methysergide mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[30]
Dihydroergotamine	DM5IKUF	Moderate	Decreased metabolism of Octreotide caused by Dihydroergotamine mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[46]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Octreotide caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[31]
Oxycodone	DMXLKHV	Moderate	Decreased metabolism of Octreotide caused by Oxycodone mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[36]
Istradefylline	DM20VSK	Moderate	Decreased metabolism of Octreotide caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[47]
Bromocriptine	DMVE3TK	Moderate	Decreased metabolism of Octreotide caused by Bromocriptine mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[48]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Octreotide caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[49]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Octreotide caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[30]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Octreotide caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[50]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Octreotide caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[51]
Everolimus	DM8X2EH	Moderate	Decreased metabolism of Octreotide caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[52]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of Octreotide caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[53]
Fentanyl	DM8WAHT	Moderate	Decreased metabolism of Octreotide caused by Fentanyl mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[54]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Octreotide caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[36]
-----------


⏷ Show the Full List of 33 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2055).
2	Emerging drugs for complications of end-stage liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):159-74.
3	FDA Approved products: Mycapssa (octreotide) oral delayed-release capsules
4	BDDCS applied to over 900 drugs
5	Schrager S, Paddock E, Dalby J, Knudsen L: Contraception in Wisconsin: a review. WMJ. 2010 Dec;109(6):326-31.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
9	P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6.
10	Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
11	Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
12	Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
13	Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
14	Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
15	Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
16	Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
17	Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
18	Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
19	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
20	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
21	Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
22	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
23	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
24	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
25	TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
26	The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
27	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
28	Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.
29	Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
30	Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
31	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
32	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
33	Product Information. Tikosyn (dofetilide) Pfizer US Pharmaceuticals, Atlanta, GA.
34	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
35	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
36	Cerner Multum, Inc. "Australian Product Information.".
37	Product Information. Lutathera (lutetium Lu 177 dotatate). Advanced Accelerator Applications, New York, NY.
38	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
39	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
40	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
41	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
43	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
44	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
45	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
46	Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
47	Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
48	Flogstad AK, Halse J, Grass P, Abisch E, Djoseland O, Kutz K, Bodd E, Jervell J, Flgstad AK, Djseland O "A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly." J Clin Endocrinol Metab 79 (1994): 461-5. [PMID: 8045964]
49	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
50	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
51	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
52	Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
53	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
54	Labroo RB, Paine MF, Thummel KE, Kharasch ED "Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implicaitons for interindividual variability in disposition, efficacy, and drug interactions." Drug Metab Dispos 25 (1997): 1072-80. [PMID: 9311623]